Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

     Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $ Diluted, Impacted by an $81.5 Million One Time Non-Recurring...

Related Keywords

Japan ,United States ,Canada ,America ,American ,Patrickj Mcenany ,Dydo Pharma ,Richardj Daly ,Development Expenses ,Company Quarterly Report On Form ,Health Canada ,Catalyst Pharmaceuticals Inc ,Company Nasdaq ,Exchange Commission ,Catalyst Pharmaceuticals ,International Number ,Third Quarter ,Net Revenues ,One Time Non Recurring ,Expense Related ,Duchenne Muscular ,Maximum Daily Dose ,Have Recently ,Upon Issuance ,Further Strengthening ,Intellectual Property ,Full Year ,Revenue Guidance ,Three Months Ended September ,Per Share ,Income Per Share ,South American ,Achievement Award ,Administrative Expenses ,Intangible Assets ,Cash Equivalents ,Quarterly Report ,Canada Dial In Number ,Dial In Number ,North America ,Fast Track ,Full Prescribing ,Safety Information ,Full Prescribing Information ,Annual Report ,Markets ,